Studies related to Symptoms of Bipolar Disorder and Chromium

A 2-year, Open-label Pilot Study Of Adjunctive Chromium In Patients With Treatment-resistant Rapid-cycling Bipolar Disorder

Effect Decrease
Trial Design Cohort
Trial Length 6+ Months
Number of Subjects 30
Sex Both Genders
Notes for this study:
In patients with bipolar disorder given between 600-800mcg chromium daily, it seemed that a minority of persons reported less depressive symptoms after three weeks (30% response as assessed by HAMD, 39% as assessed by MADRS) with no apparent benefit reported for manic symptoms nor any longer term benefits being reported due to dropouts.

No placebo control used in this study.